- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06086938
pBFS-guided cTBS Combined With iTBS Over the Superior Frontal Gyrus for Aphasia After Ischemic Stroke
Personalized Brain Functional Sector-guided Continuous Theta Burst Stimulation Combined With Intermittent Theta Burst Stimulation Therapy Targeting at the Superior Frontal Gyrus for Aphasia After Ischemic Stroke: a RCT
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Increasing evidence suggests that rTMS has been effective in treating various psychological and neurological diseases, including treating post-stroke symptoms. Using the personalized brain functional sectors (pBFS) technique, we could precisely identify individualized brain functional networks and the personalized language-related stimulation site based on the resting-state functional MRI data. The current study proposes to conduct a double-blinded, randomized and parallel controlled design trial, to investigate the efficacy and safety of pBFS-guided personalized cTBS combined with iTBS intervention in post-stroke aphasic patients.
Subjects will be randomly assigned to the following two groups: active TBS(cTBS+iTBS)group, or a sham TBS(sham cTBS+sham iTBS)group. The allocation ratio will be 1:1. The stimulation protocol consisted of a 3-week treatment, with five consecutive days each week (totally 15 day-treatment) .The stimulation procedure will be assisted with real-time neuronavigation to ensure its precision.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ruiqi Pan
- Phone Number: 010-80726688
- Email: ruiqipanedu@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient's age ranges from 35 to 75 years old (including 35 and 75 years old);
- Meet the diagnostic criteria for acute ischemic stroke (diagnosed according to the "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke" written by the American Heart Association/American Stroke Association in 2019 and the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018" compiled by the Neurology Branch of the Chinese Medical Association in 2018), with lesions in the left hemisphere, and a duration of ≥15 days and ≤3 months;
- Diagnosed as aphasia patient according to the Chinese version of Western Aphasia Battery (WAB), with a WAB-aphasia quotient of less than 93.8 points;
- First onset of stroke;
- Normal functioning language abilities before the stroke, with Mandarin as their native language and an educational level higher than primary school;
- Understand the trial and signed the informed consent form.
Exclusion Criteria:
- Combined severe dysarthria (NIHSS item 10 score ≥2 points);
- Aphasia caused by bilateral hemisphere stroke, brain tumor, traumatic brain injury, Parkinson's disease, motor neuron disease, or other diseases;
- Patients with implanted electronic devices such as cardiac pacemakers, cochlear implants, or other metal foreign bodies, or those with MRI contraindications such as claustrophobia or TMS treatment contraindications;
- History of epilepsy;
- Patient with concomitant severe systemic diseases affecting the heart, lungs, liver, kidneys, etc., and uncontrolled by conventional medication, as detected and confirmed through laboratory testing and examination;
- Patients with consciousness disorders (NIHSS 1(a) score ≥1);
- Patients with malignant hypertension;
- Patients with severe organic diseases, such as malignant tumors, with an expected survival time of less than 1 year;
- Patients with severe hearing, visual, cognitive impairment or inability to cooperate with the trial;
- Patients with severe depression, anxiety, or diagnosed with other mental illnesses that prevent them from completing the trial;
- Patients who have received other neuroregulatory treatments such as TMS, transcranial electric stimulation, etc. in the 3 months prior to enrollment;
- Patients with a history of alcoholism, drug abuse, or other substance abuse;
- Patients with other abnormal findings that the researchers judge are not suitable for participation in this trial;
- Patients who are unable to complete follow-up due to geographical or other reasons;
- Women of childbearing age who are currently pregnant, breastfeeding, or planning or may become pregnant during the trial;
- Patients who are currently participating in other clinical trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: active TBS group
active TBS combined with speech language therapy
|
Daily TBS treatment consists of the following combination: active 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + active 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + active 600-pulse cTBS applied to the SFG in the unaffected hemisphere + active 600-pulses iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of TBS intervention. The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks. |
Sham Comparator: sham TBS group
sham TBS combined with speech language therapy
|
Daily sham TBS treatment consists of the following combination: sham 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + sham 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + sham 600-pulse cTBS applied to the SFG in the unaffected hemisphere + 600-pulse sham iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of sham TBS intervention. The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Western Aphasia Battery scores
Time Frame: baseline, end of the 3-week therapy
|
The first four subsets of the WAB (Spontaneous Speech, Auditory verbal comprehension, Repetition, Naming and word finding) will be used to evaluate the participants' language ability impairments.
A Chinese adapted version of WAB will be used.
The scores from all four subsets will be calculated as an Aphasia Quotient (ranging from 0 to 100), with lower Aphasia Quotients indicating poorer language abilities.
|
baseline, end of the 3-week therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chinese-version Stroke and Aphasia Quality of Life Scale 39-generic version (SAQOL-39g)
Time Frame: baseline,end of the 3-week therapy,90 days after treatment initiation
|
The SAQOL-39g is a quality of life assessment tool that is used to evaluate the impact of stroke and aphasia on a patient's quality of life.
It consists of 39 items that cover a range of domains related to the patient's quality of life, such as communication, physical functioning, mood, and social support.
The items are rated on a 5-point Likert scale ranging from "not at all" to "very much", with higher scores indicating better quality of life.
|
baseline,end of the 3-week therapy,90 days after treatment initiation
|
Change in the Western Aphasia Battery scores
Time Frame: baseline, end of the 5-day therapy, 90 days after treatment initiation
|
The first four subsets of the WAB (Spontaneous Speech, Auditory verbal comprehension, Repetition, Naming and word finding) will be used to evaluate the participants' language ability impairments.
A Chinese adapted version of WAB will be used.
The scores from all four subsets will be calculated as an Aphasia Quotient (ranging from 0 to 100), with lower Aphasia Quotients indicating poorer language abilities.
|
baseline, end of the 5-day therapy, 90 days after treatment initiation
|
Boston Diagnostic Aphasia Examination Severity Ratings
Time Frame: baseline,end of the 3-week therapy,90 days after treatment initiation
|
The Boston Diagnostic Aphasia Examination (BDAE) Severity Ratings is a clinical tool used to evaluate the severity and type of aphasia in individuals.
The assessment includes four domains: communication abilities, language content, speech sound production and response abilities.BDAE severity ratings range from level 0 to level 5, with lower scores indicating more severe aphasia.
|
baseline,end of the 3-week therapy,90 days after treatment initiation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Hesheng Liu, Ph.D., Changping Laboratory
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Language Disorders
- Communication Disorders
- Speech Disorders
- Stroke
- Ischemic Stroke
- Ischemia
- Aphasia
Other Study ID Numbers
- CPSA07BJ40
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aphasia
-
University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedStroke | Aphasia | Stroke, Ischemic | Aphasia, Broca | Aphasia, Anomic | Aphasia, Global | Aphasia, Fluent | Aphasia, Mixed | Aphasia, Jargon | Aphasia, Expressive | Aphasia, ConductionUnited States
-
University of Texas at AustinUniversity of California, San Francisco; National Institute on Deafness and...Active, not recruitingPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Semantic Memory Disorder | Nonfluent Aphasia, Progressive | Aphasia, ProgressiveUnited States
-
Institute for Bioengineering of CataloniaHospital Universitari Joan XXIII de Tarragona.; Universitat Pompeu FabraCompletedAphasia | Aphasia, Broca | Aphasia, Wernicke | Aphasia, Fluent | Aphasia, NonfluentSpain
-
Flint Rehabilitation Devices, LLCUniversity of TexasCompleted
-
Mayo ClinicNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingPrimary Progressive Aphasia | Apraxia of Speech | PPA | Non-fluent Aphasia | Primary Progressive Non-fluent AphasiaUnited States
-
University of California, BerkeleyUniversity of California, San Francisco; California State University, East Bay and other collaboratorsRecruitingAphasia | Aphasia, Acquired | Aphasia Non Fluent | Aphasia, FluentUnited States
-
Mayo ClinicCompletedPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Apraxia of Speech | Primary Progressive Nonfluent Aphasia | PPA | Non-fluent Aphasia | Progressive AphasiaUnited States
-
Montreal Heart InstituteActive, not recruitingNeurodegenerative Diseases | Primary Progressive Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Non-fluent AphasiaCanada
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia | Logopenic Progressive Aphasia | Non-Fluent Primary Progressive AphasiaUnited States, Canada
-
University of British ColumbiaTerminatedPrimary Progressive Nonfluent AphasiaCanada
Clinical Trials on active cTBS combined with iTBS
-
University of California, San DiegoCompletedCognitive ControlUnited States
-
Medical University of South CarolinaVirginia Tech Carilion School of Medicine and Research InstituteTerminatedAddiction | Craving | Nicotine | Smoking, CigaretteUnited States
-
The University of New South WalesCompleted
-
Jakub AntczakInstitute of Psychiatry and Neurology, WarsawNot yet recruitingBipolar Disorder | Unipolar DepressionPoland
-
Mclean HospitalMassachusetts General HospitalRecruitingObsessive-Compulsive DisorderUnited States
-
Jean-Marie AnnoniCompleted
-
Medical University of South CarolinaSouth Carolina Clinical & Translational Research Institute (SCTR)CompletedPain | Chronic Pain | Opioid Dependence | Opioid UseUnited States
-
Xijing HospitalEnrolling by invitation
-
Changping LaboratoryRecruitingAphasia | Stroke, IschemicChina
-
University of BernCompletedSchizophrenia and Related DisordersSwitzerland